Conference Coverage

FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD


 

FROM ACC 2021

Hypothesis-generating findings

The new findings reported by Dr. Filippatos “should be considered hypothesis generating. Until we have more information, upstream therapies, including mineralocorticoid receptor antagonists [MRAs, the umbrella drug class that includes finerenone], should be used in appropriate patient populations based on defined benefits with the hope they will also reduce the development of AFib and atrial flutter over time,” Gerald V. Naccarelli, MD, and coauthors wrote in an editorial that accompanied the report (J Am Coll Cardiol. 2021 May 17. doi: 10.1016/j.jacc.2021.04.080).

The FIDELIO-DKD trial randomized 5,734 patients at 913 sites in 48 countries, including 461 patients with a history of AFib. The observed link of finerenone treatment with a reduced incidence of AFib appeared consistent regardless of patients’ age, sex, race, their kidney characteristics at baseline, baseline levels of systolic blood pressure, serum potassium, body mass index, A1c, or use of glucose-lowering medications.

Finerenone belongs to a new class of MRAs that have a nonsteroidal structure, in contrast with the MRAs spironolactone and eplerenone. This means that finerenone does not produce steroidal-associated adverse effects linked with certain other MRAs, such as gynecomastia, and may also differ in other actions.

FIDELIO-DKD was sponsored by Bayer, the company developing finerenone. Dr. Filippatos has received lecture fees from or participated in the direction of trials on behalf of Bayer, as well as for Amgen, Boehringer Ingelheim, Medtronic, Novartis, Servier, and Vifor. Dr. Curtis is an adviser to and receives honoraria from St. Jude Medical, and receives honoraria from Medtronic. Dr. Naccarelli has been a consultant to Acesion, ARCA, GlaxoSmithKline, Janssen, Milestone, Omeicos, and Sanofi. His coauthors had no disclosures.

Pages

Recommended Reading

FDA finalizes medical device cybersecurity guidance
Type 2 Diabetes ICYMI
Unrecognized MI common with impaired fasting glucose
Type 2 Diabetes ICYMI
FDA: CT scans safe for patients with electronic medical devices
Type 2 Diabetes ICYMI
Diabetes treatment costs doubled in Sweden since 2006
Type 2 Diabetes ICYMI
Sacubitril/valsartan enhances glycemic control in diabetic patients with heart failure
Type 2 Diabetes ICYMI
MDedge Daily News: Which diabetes drug boosts survival best?
Type 2 Diabetes ICYMI
Weight loss surgery linked to lower CV event risk in diabetes
Type 2 Diabetes ICYMI
Dapagliflozin given Fast Track status for HF therapy
Type 2 Diabetes ICYMI
Thirteen percent of patients with type 2 diabetes have major ECG abnormalities
Type 2 Diabetes ICYMI
FDA blazes path for ‘real-world’ evidence as proof of efficacy
Type 2 Diabetes ICYMI